Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up
A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care.
SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven
Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S.
The Missing Piece in Lowering the Cost of Care: Predictability
When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases, people wait too long, leaving an ER visit as the path of least resistance.
Epic MyChart Phishing Scam Hits Health Systems: What Providers Should Do
More than a dozen health systems are warning patients of a phishing campaign impersonating Epic's MyChart portal with fake Medicare rewards and faux login pages. Experts say the scam exposes a deeper problem: patients can't be expected to spot increasingly polished fakes, so the responsibility falls on providers to communicate in ways that build trust.
FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy
Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological disorders, each with blockbuster potential.